Organon & Co. (NYSE: OGN) announced fourth quarter and full-year 2025 financial results, with total revenue declining 3% to USD 6.2 billion on a constant currency basis. The women’s health-focused pharmaceutical company faced headwinds from NuvaRing erosion, established brand LOE impacts, and biosimilar pricing pressure, partially offset by fertility growth and Hadlima biosimilar gains. The JADA system sale to Laborie Medical Technologies (early 2026) removes a USD 74 million revenue contributor, though currency translation is expected to offset the loss.
Financial Performance Summary
Metric
2025 Result
YoY Change (CC)
Key Driver
Total Revenue
USD 6.2 billion
-3%
Women’s Health decline; Established Brands LOE; Biosimilar pricing pressure
Forward‑Looking Statements This brief contains forward‑looking statements regarding Organon’s 2026 revenue stabilization, JADA divestiture execution, and biosimilar competitive positioning. Actual results may differ due to women’s health market dynamics, biosimilar pricing volatility, and currency translation variability.-Fineline Info & Tech
By Fineline Cube 